Table 4.

Multivariable adjusted associations of adipokine levels and endometrial cancer risk stratified by MHT use

	Non-Current Usersa		Current Users
	Case/Control	MV & BMI & Estradiol	Case/Control	MV & BMI & Estradiol	p-valueb
Adiponectin (μg/ml)
≤ 11.89	53/57	Ref (1.00)	26/50	Ref (1.00)	0.005
11.90 – 18.10	23/57	0.56 (0.25-1.23)	22/51	0.67 (0.32-1.41)
> 18.10	10/59	0.25 (0.08-0.75)	31/52	1.19 (0.56-2.53)
p-trend		0.011		0.645
Leptin (ng/ml)
≤ 11.03	6/46	Ref (1.00)	28/63	Ref (1.00)	0.003
11.04 – 22.55	21/61	2.00 (0.57-7.05)	30/47	1.18 (0.56-2.45)
> 22.55	59/66	4.72 (1.15-19.38)	21/43	0.70 (0.24-2.03)
p-trend		0.019		0.640
Visfatin (ng/ml)
≤ 0.54	10/29	Ref (1.00)	12/33	Ref (1.00)	0.842
0.55 – 0.93	14/30	0.58 (0.08-4.06)	17/33	0.94 (0.16-5.37)
> 0.93	23/35	1.71 (0.15-20.12)	18/29	2.84 (0.53-15.11)
p-trend		0.585		0.163
Adiponectin/Leptin (μg)
≤ 0.55	62/65	Ref (1.00)	19/43	Ref (1.00)	0.0002
0.56 – 1.43	17/56	0.30 (0.10-0.84)	32/52	2.16 (0.86-5.43)
> 1.43	7/52	0.15 (0.03-0.61)	28/58	1.92 (0.62-5.91)
p-trend		0.006		0.350

MV=multivariable: adjusted for family history of breast or endometrial cancer, education level, parity, history of diabetes diagnosis, oral contraceptive use, and current smoking status. Odds ratios (OR) and 95% CIs were estimated by conditional logistic regression (matched sets: 86 cases and 173 controls for never/former users and 79 cases and 153 controls for current users). Tertiles of adipokines based on the control distribution. Estradiol and BMI were included as continuous terms in the model.

^aIncludes never and former MHT users.

^bp-value calculated from a likelihood ratio test comparing unconditional multivariable logistic regression models with and without an interaction term for the adipokine and current MHT use adjusting for matching factors and the variables included in the MV conditional logistic regression models.